Rational design for variability minimization in bioanalytical method validation: Illustration with LC-MS/MS assay method for terbinafine estimation in human plasma

Biomedical Chromatography

Volumn 24, Issue 11, 2010, Pages 1168-1178

  Gurule, Sanjay ^a   Khuroo, Arshad ^a   Monif, Tausif ^a   Goswami, Dipanjan ^a   Saha, Arabinda ^a  

^a RANBAXY LABORATORIES LTD   (India)

Author keywords

LCMS MS; Method development; Pharmacokinetic evaluation; Terbinafine; Validation approach

Indexed keywords

ASSAYS; EXTRACTION; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

BIOANALYTICAL METHODS; DESIGN FOR VARIABILITIES; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; METHOD DEVELOPMENT; PHARMACOKINETIC EVALUATION; RATIONAL DESIGN; TERBINAFINE; VALIDATION APPROACH;

PLASMA STABILITY;

NAFTIFINE; TERBINAFINE;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; EXTRACTION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; RELIABILITY; SOLID PHASE EXTRACTION; STANDARD;

EID: 77958502218     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1423     Document Type: Article

References (17)

1. Almeida S, Filipe A, Vallée F, Tanguay M, Larouche R and Lainesse A. Comparative bioavailability of two formulations of terbinafine. Data from a crossover, randomized, openlabel bioequivalence study in healthy volunteers. Arzneimittelforschung 2004; 54: 757-762.
2. Brignol N, Bakhtiar R, Dou L, Majumdar T and Tse FL. Quantitative analysis of terbinafine (Lamisil) in human and minipig plasma by liquid chromatography tandem mass spectrometry. Rapid Communication in Mass Spectrometry 2000; 14: 141-149.
3. th edn. Lippincott, Williams & Wilkins: Philadelphia, PA, 2005; 8.
4. Chambers E, WagrowskiDiehl D, Lu Z and Mazzeo J. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. Journal of Chromatography B 2007; 852: 22-34.
5. Chow CS and Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker: New York, 1992.
6. Denouël J, Keller HP, Schaub P, Delaborde C and Humbert H. Determination of terbinafine and its desmethyl metabolite in human plasma by highperformance liquid chromatography. Journal of Chromatography B Biomedical Application 1995; 663: 353-359.
7. de Oliveira CH, BarrientosAstigarraga RE, de Moraes MO, Bezerra FA, de Moraes ME and de Nucci G. Terbinafine quantification in human plasma by high performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to a bioequivalence study. Therapeutic Drug Monitoring 2001; 23: 709-716.
8. Dotsikas Y, Apostolou C, Kousoulos C, Tsatsou G and Loukas YL. An improved highthroughput liquid chromatographic/tandem mass spectrometric method for terbinafine quantification in human plasma, using automated liquid-liquid extraction based on 96well format plates. Biomedical Chromatography 2007; 21: 201-208.
9. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. US Food and Drug Administration, Drug Evaluation and Research: Rockville, MD, March 2003. Available from: pdf (accessed 22 February 2007).
10. Jiang X, Wang N, ZunJian Z, Tian Y and Chen Y. Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after singledose administration in Chinese healthy subjects. ArzneimittelForschung 2008; 58: 363-366.
11. Kuzner J, Kozuh Erzen N and DrobnicKosorok M. Determination of terbinafine hydrochloride in cat hair by two chromatographic methods. Biomedical Chromatography 2001; 15: 497-502.
12. Matysová L, Solich P, Marek P, Havlíková L, Nováková L and Sícha J. Separation and determination of terbinafine and its four impurities of similar structure using simple RPHPLC method. Talanta 2006; 68: 713-720.
13. Rossen K, Adydin E, John VDMM and Serder A. Clinical relevance of bioequivalence acceptance criteria: the example of terbinafine. ArzneimittelForschung 2003; 53: 289-293.
14. Schuirmann DJ. A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmacy 1987; 15: 657.
15. Shargel L, WuPong S and Yu A. Applied Biopharmaceutics and Pharmacokinetics: Bioavailability and Bioequivalence, 5th edn. McGraw-Hill: New York, 2005; 161.
16. Yamaoka T, Tanigawa Y, Nakagawa T and Uno T. A pharmacokinetic analysis program (multi) for microcomputer. Journal of Pharmacobiodynamics 1981; 4: 879-885.
17. Zehender H, Denouël J, Roy M, Le Saux L and Schaub P. Simultaneous determination of terbinafine (Lamisil) and five metabolites in human plasma and urine by highperformance liquid chromatography using online solidphase extraction. Journal of Chromatography B Biomedical Application 1995; 664: 347-355.